MAGIC Study

A Randomised, Controlled Trial of Pre-  and  Post- Operative Chemotherapy in Patients with Operable Gastric and Lower Oesophageal Cancer.

Share

Trial Status

Completed

Cancer Type

Oesophageal Cancer

Aim

Surgery is the standard treatment for cancers of the stomach (gastric) and lower oesophagus (gullet) that can be removed with an operation, but the cancer often comes back (recurs) despite the best surgery. This trial will determine if adding chemotherapy two months before and two months after surgery improves recurrence and cure rates.

Trial Status

Completed

Cancer Type

Oesophageal Cancer

Publication Reference

Cunningham D, Allum W, Stenning S, Thompson J, Van de Velde C, Nicolson M, Scarffe J, Lofts F, Falk S, Iveson T, Smith D, Langley R, Verma M, Weeden S, Chua Y, for the MAGIC trial participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine 2007; 355(1): 11-20.

Conference Presentation Reference

Storey D; Australian Management Committee. MAGIC-MRC randomised trial of pre- and post-operative chemotherapy for operable gastric cancer: Insights from the Australasian Gastro-Intestinal Trials Group feasibility study (AG9601). 27th Annual Scientific Meeting of the Clinical Oncological Society of Australia; 28 Nov–1 Dec 2000; Adelaide.

Aim

Surgery is the standard treatment for cancers of the stomach (gastric) and lower oesophagus (gullet) that can be removed with an operation, but the cancer often comes back (recurs) despite the best surgery. This trial will determine if adding chemotherapy two months before and two months after surgery improves recurrence and cure rates.

Principal Investigator

Prof  Michael Findlay, Medical Oncologist, Auckland Hospital, New Zealand

Funding

Cancer Council NSW